In acute myeloid leukemia, researchers applied cryogel-housed MSCs modulated to secrete a bispecific (anti-CD3 and anti-CD33) antibody for maximizing cancer immunotherapy [128]. This evidence concerns the gene CD33 and acute myeloid leukemia.